This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Medical Ethics  • Randomized Controlled Trial  • Dermatologic Disorders, Other  • Alert me on articles by topic

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In an article that appeared in the "Evidence-Based Dermatology: Research Commentary" section of the ARCHIVES, Dr Williams¹ raised several questions concerning an article that reported the results of a study on 1% pimecrolimus cream for the treatment of mild and moderate atopic dermatitis in children and adolescents.² As the authors of that article, we would like to respond to Dr Williams' comments, because it is our belief that the efficacy of topical pimecrolimus has been evidentially demonstrated.

Dr Williams asks, "[H]ow well was the study reported? (ie, should we believe the results?) . . . ." The reporting of a study is limited by the scientific publication process, which requires concise summaries of studies, with aggressive editing of text and figures prior to submission and during the journal's editorial process. Some of the details of the study design were not included in the Journal of the American Academy of Dermatology . . . [Full Text of this Article]

Lawrence F. Eichenfield, MD
Children's Hospital and Health Center
Pediatric And Adolescent Dermatology
8010 Frost St, Suite 602
San Diego, CA 92123
(e-mail: leichenfield@ucsd.edu)

Anne W. Lucky, MD; Mark Boguniewicz, MD; Richard G. B. Langley, MD; Robert Cherill; Katharine Marshall
San Diego

RELATED ARTICLE

1% Pimecrolimus Cream for Atopic Dermatitis—Reply
Hywel Williams
Arch Dermatol. 2003;139(10):1370-1371.
EXTRACT | FULL TEXT